Released Apr 13, 2018, after the close
10-K filed Apr 13, 2018, 103 days after period end · 0001193125-18-117053
Q4 2017 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$8.79M-$8.79M derivedN/M vs Q4 2016N/M vs Q3 2017
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$8,578,000N/M
Operating Cash Flowderived-$1,742,000N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2017dderived from reported figures | Q4 2016dderived from reported figures | Q4 2015dderived from reported figures | Q4 2014dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | — | — | $3.20M |
| Net Income | -$8.79M | $352.00K | -$19.68M | -$7.96M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR